1. Adverse events in cancer immunotherapy;Abdel-Wahab;Adv Exp Med Biol,2017
2. Administration, US Food and Drug, 2020. 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf〉. Accessed 23/06/2023.
3. Administration, US Food and Drug, 2022. 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf〉. Accessed 23/06/2023.
4. Agency, European Medicines, 2020. 〈https://www.ema.europa.eu/en/documents/assessment-report/blenrep-epar-public-assessment-report_en-0.pdf〉. Accessed 23/06/2023.
5. Agency, European Medicines, 2022. 〈https://www.ema.europa.eu/en/documents/rmp-summary/padcev-epar-risk-management-plan-summary_en.pdf〉. Accessed 23/06/2023.